{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T12:19:06Z","timestamp":1768047546806,"version":"3.49.0"},"reference-count":21,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,8,31]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Factor XIII (FXIII) is a thrombin-activated protransglutaminase that plays a key role in blood clot formation. Congenital FXIII A-subunit deficiency represents a rare bleeding disorder that affects one in 2\u20133\u2009million individuals worldwide and is treated with recombinant FXIII (rFXIII). However, due to the rarity of the disease, clinicians are often left to weigh individual variation in FXIII activity and\/or symptoms to optimally guide dosing. Cases often become further complicated when patients experience refractory bleeding, which can be difficult to treat. This report describes an approach to rFXIII dosing in two patients who required deviation from standard protocols to maintain therapeutic FXIII troughs. We highlight limitations in our understanding of FXIII deficiency management, while also providing an example of the application of pharmacokinetic data to individualise therapy for improved outcomes. Finally, the case reminds us of the importance of patient-centered, cost-conscious care and multidisplinary teamwork in complex cases.<\/jats:p>","DOI":"10.1136\/bcr-2020-241501","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T12:46:10Z","timestamp":1631796370000},"page":"e241501","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Patient-centered approach to managing factor XIII deficiency"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7712-4605","authenticated-orcid":false,"given":"Varun","family":"Iyengar","sequence":"first","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Montcrieff","sequence":"additional","affiliation":[{"name":"Hasbro Children's Hospital, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salley","family":"Pels","sequence":"additional","affiliation":[{"name":"Hasbro Children's Hospital, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"2025082712105518000_14.9.e241501.1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-0036-1572326","article-title":"Diagnosis and management of congenital and acquired FXIII deficiencies","volume":"42","author":"Muszbek","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"2025082712105518000_14.9.e241501.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01857.x"},{"key":"2025082712105518000_14.9.e241501.3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00338.x"},{"key":"2025082712105518000_14.9.e241501.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00951.x"},{"key":"2025082712105518000_14.9.e241501.5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.2.e32"},{"key":"2025082712105518000_14.9.e241501.6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/hae.12616","article-title":"Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency","volume":"21","author":"Brand-Staufer","year":"2015","journal-title":"Haemophilia"},{"key":"2025082712105518000_14.9.e241501.7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/MBC.0b013e328300c7ff","article-title":"An unusual clinical presentation of factor XIII deficiency and issues relating to the monitoring of factor XIII replacement therapy","volume":"19","author":"Dargaud","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2025082712105518000_14.9.e241501.8","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/jth.13748","article-title":"Recombinant factor\u00a0XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase\u00a03b trial results","volume":"15","author":"Kerlin","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2025082712105518000_14.9.e241501.9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1571343"},{"key":"2025082712105518000_14.9.e241501.10","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/jth.13772","article-title":"Minimal factor XIII activity level to prevent major spontaneous bleeds","volume":"15","author":"Menegatti","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2025082712105518000_14.9.e241501.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386045"},{"key":"2025082712105518000_14.9.e241501.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00944.x"},{"key":"2025082712105518000_14.9.e241501.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04653.x"},{"key":"2025082712105518000_14.9.e241501.14","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/hae.13603","article-title":"Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors","volume":"24","author":"Beckman","year":"2018","journal-title":"Haemophilia"},{"key":"2025082712105518000_14.9.e241501.15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.blre.2018.01.001","article-title":"Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play?","volume":"32","author":"Hazendonk","year":"2018","journal-title":"Blood Rev"},{"key":"2025082712105518000_14.9.e241501.16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.thromres.2020.05.005","article-title":"Pharmacokinetics for haemophilia treaters: meaning of pK parameters, interpretation pitfalls, and use in the clinic","volume":"192","author":"Delavenne","year":"2020","journal-title":"Thromb Res"},{"key":"2025082712105518000_14.9.e241501.17","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/pbc.24339","article-title":"Importance of pharmacokinetics in the management of hemophilia: importance of pharmacokinetics in hemophilia","volume":"60","author":"Barnes","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2025082712105518000_14.9.e241501.18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12708"},{"key":"2025082712105518000_14.9.e241501.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.11.040"},{"key":"2025082712105518000_14.9.e241501.20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0031-1273094","article-title":"Factor XIII and venous thromboembolism","volume":"37","author":"Bereczky","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"2025082712105518000_14.9.e241501.21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1997.00091.x"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-241501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:11:02Z","timestamp":1756321862000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-241501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,16]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bcr-2020-241501"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-241501","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}